On Wednesday, Advanced Semiconductor Engineering (ADR) (NYSE:ASX)’s shares declined -1.84% to $6.94.
Advanced Semiconductor Engineering (ADR) (ASX) hosted the ASE Group 2014 Best Supplier Awards ceremony, an event specially organized to recognize and honor suppliers integral to ASE’s ongoing success. Representatives from 126 companies, supplying equipment, raw material, information technology, logistics, and various other products and services to ASE, were in attendance. A total of 28 awards were presented to the 34 suppliers who had demonstrated extraordinary performance in their support to ASE throughout 2014.
Over the past year, ASE administration has relentlessly focused on corporate sustainability within its supply administration, resulting in the following developments:
- Membership in the Electronic Industry Citizenship Coalition (EICC): ASE became a member of the EICC in February 2015, and this membership underscores the noteworthystrides ASE has taken to enhance its commitment to environmental and social governance, both within ASE operations in addition to throughout its broader supply chain.
- Launch of the ASE Guidelines for Supply Excellence – ‘SMILE 2ART’: Creation of a framework that is Sustainable, Manageable, Innovative, Lean and Ethical, to build an Advanced, Resilient and Trusted supply chain network.
Advanced Semiconductor Engineering, Inc. provides semiconductor packaging and testing services in the United States, Taiwan, Asia, Europe, and internationally. It operates through Packaging, Testing, and Electronic Manufacturing Services (EMS) segments.
Shaw Communications Inc (USA) (NYSE:SJR)’s shares dropped -1.82% to $22.08.
Shaw Communications Inc (USA) (SJR) declared that its Board of Directors has declared monthly dividends of $0.09875 on the Class B Non-Voting Participating Shares and $0.098542 on the Class A Participating Shares, payable on each of June 29, July 30 and August 28, 2015 to holders of record at the close of business on June 15, July 15 and August 14, 2015, respectively.
Shaw Communications Inc., together with its auxiliaries, provides broadband cable television, Internet, digital phone, telecommunication, direct-to-home satellite, satellite distribution, and programming content services to residential and business customers in Canada and the United States.
At the end of Wednesday’s trade, Accuray Incorporated (NASDAQ:ARAY)‘s shares dipped -1.78% to $9.36.
Accuray Incorporated (ARAY) will report results for its third quarter ended March 31, 2015 on April 30, 2015 after the market close. Administration will host a conference call to review the results at 1:30 p.m. PT/4:30 p.m. ET on the same day.
Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body.
Celldex Therapeutics, Inc. (NASDAQ:CLDX), ended its Wednesday’s trading session with -1.75% loss, and closed at $28.07.
Celldex Therapeutics, Inc. (CLDX) declared that data from the Phase 2 EMERGE study of glembatumumab vedotin in metastatic breast cancer have been published in the Journal of Clinical Oncology. The data from this study supported the initiation of the ongoing, pivotal Phase 2 METRIC study in patients with triple negative breast cancers that over-express glycoprotein NMB (gpNMB). Glembatumumab vedotin is an antibody-drug conjugate that targets and binds to gpNMB, a protein expressed by multiple tumor types, counting breast cancer. Overexpression of gpNMB has been shown to promote the invasion and metastasis of cancer and has been associated with poor clinical outcome.
Celldex Therapeutics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes novel therapeutics for human health care in the United States. The company’s lead drug candidates comprise rindopepimut (CDX-110), a targeted immunotherapeutic in a pivotal Phase III study for the treatment of front-line glioblastoma, in addition to in Phase II study for the treatment of recurrent glioblastoma; and Glembatumumab vedotin (CDX-011), a targeted antibody-drug conjugate in a randomized Phase IIb study for the treatment of triple negative breast cancer, in addition to in Phase II study for the treatment of metastatic melanoma.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
